AIM ImmunoTech Inc. (AIM) Stock Profile — Insider Trades & Financials

Smart-Money SignalNeutral · 54/100— Insiders are net buyers over 90 days ($13K, 4 buys vs 0 sales)

Revenue$26.0K

Net Income-$3.8M

EPS$-0.96

Market Cap$5.0M

Price Performance

Historical data including institutional events

Company Profile

CEO Thomas K. Equels, J.D. COO Peter W. Rodino III, J.D. CFO Ellen Lintal

CEO & Executive Director

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.

Founded: 1966
Employees: 1
Headquarters: OCALA, FL, United States
Website: aimimmuno.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Feedback

Smart-Money SignalNeutral · 54/100— Insiders are net buyers over 90 days ($13K, 4 buys vs 0 sales)

Revenue$26.0K

Net Income-$3.8M

EPS$-0.96

Market Cap$5.0M

Price Performance

Historical data including institutional events

Company Profile

CEO Thomas K. Equels, J.D. COO Peter W. Rodino III, J.D. CFO Ellen Lintal

CEO & Executive Director

Founded: 1966
Employees: 1
Headquarters: OCALA, FL, United States
Website: aimimmuno.com

Peer ComparisonRevenue ($B)

▾

Smart-Money Signal

90-DAY POSTURE

54/ 100

NEUTRAL

Insiders are net buyers over 90 days ($13K, 4 buys vs 0 sales). Smart-money posture is balanced.

Insider flow · 90d$13K

Congress flow · 90dno activity

10b5-1 share—

Cluster selling0 officers

Price vs 52w6% of high

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER BUYThomas K. Equels bought AIMApr 11, 2025

INSIDER BUYTed D. Kellner bought AIMApr 11, 2025

INSIDER BUYThomas K. Equels bought AIMJun 12, 2025

INSIDER BUYThomas K. Equels bought AIMJun 13, 2025

INSIDERDavid I. Chemerow (Director) OTHER AIMMar 6, 2026

INSIDERThomas K. Equels (CEO & President) OTHER AIMMar 6, 2026

INSIDER EXERCISE / CONVERSIONDavid I. Chemerow (Director) EXERCISE / CONVERSION AIMMar 12, 2026

INSIDER EXERCISE / CONVERSIONThomas K. Equels (CEO & President) EXERCISE / CONVERSION AIMMar 12, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 14, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 15, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 16, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 17, 2026

⚡

Core Efficiency

ROE?

-48.92%

ROA?

-29.75%

D/E Ratio?

0.64

Op. Margin?

-13511.54%

📊

Profitability Ratios

Net Margin?

-14569.23%

Current Ratio?

2.11

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 24, 2026 (in 42 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 24, 2026

Predicted10-Q

Aug 7, 2026

10-QQ2 202638d after period end

May 15, 2026

10-QQ1 202645d after period end

Mar 27, 2026

10-KQ4 202586d after period end

Mar 27, 2026

10-KFY 202586d after period end

Nov 17, 2025

10-QQ3 202548d after period end

Aug 14, 2025

10-QQ2 202545d after period end

May 15, 2025

10-QQ1 202545d after period end

Mar 27, 2025

10-KQ4 202486d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-07

SEC Metadata

2mo ago

Latest filing: 2026-08-07

Loading company sections...

Smart-Money Signal

90-DAY POSTURE

54/ 100

NEUTRAL

Insiders are net buyers over 90 days ($13K, 4 buys vs 0 sales). Smart-money posture is balanced.

Insider flow · 90d$13K

Congress flow · 90dno activity

10b5-1 share—

Cluster selling0 officers

Price vs 52w6% of high

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER BUYThomas K. Equels bought AIMApr 11, 2025

INSIDER BUYTed D. Kellner bought AIMApr 11, 2025

INSIDER BUYThomas K. Equels bought AIMJun 12, 2025

INSIDER BUYThomas K. Equels bought AIMJun 13, 2025

INSIDERDavid I. Chemerow (Director) OTHER AIMMar 6, 2026

INSIDERThomas K. Equels (CEO & President) OTHER AIMMar 6, 2026

INSIDER EXERCISE / CONVERSIONDavid I. Chemerow (Director) EXERCISE / CONVERSION AIMMar 12, 2026

INSIDER EXERCISE / CONVERSIONThomas K. Equels (CEO & President) EXERCISE / CONVERSION AIMMar 12, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 14, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 15, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 16, 2026

INSIDER BUYThomas K. Equels (CEO & President) BUY AIMSep 17, 2026

⚡

Core Efficiency

ROE?

-48.92%

ROA?

-29.75%

D/E Ratio?

0.64

Op. Margin?

-13511.54%

📊

Profitability Ratios

Net Margin?

-14569.23%

Current Ratio?

2.11

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 24, 2026 (in 42 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 24, 2026

Predicted10-Q

Aug 7, 2026

10-QQ2 202638d after period end

May 15, 2026

10-QQ1 202645d after period end

Mar 27, 2026

10-KQ4 202586d after period end

Mar 27, 2026

10-KFY 202586d after period end

Nov 17, 2025

10-QQ3 202548d after period end

Aug 14, 2025

10-QQ2 202545d after period end

May 15, 2025

10-QQ1 202545d after period end

Mar 27, 2025

10-KQ4 202486d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-07

SEC Metadata

2mo ago

Latest filing: 2026-08-07

AIM ImmunoTech Inc.

Price Performance

Company Profile

AIM ImmunoTech Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

AIM ImmunoTech Inc.

Price Performance

Company Profile

The morning brief, before the bell.

AIM ImmunoTech Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades